GB201700814D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB201700814D0
GB201700814D0 GBGB1700814.5A GB201700814A GB201700814D0 GB 201700814 D0 GB201700814 D0 GB 201700814D0 GB 201700814 A GB201700814 A GB 201700814A GB 201700814 D0 GB201700814 D0 GB 201700814D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1700814.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Liverpool
Liverpool School of Tropical Medicine
Original Assignee
University of Liverpool
Liverpool School of Tropical Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Liverpool, Liverpool School of Tropical Medicine filed Critical University of Liverpool
Priority to GBGB1700814.5A priority Critical patent/GB201700814D0/en
Publication of GB201700814D0 publication Critical patent/GB201700814D0/en
Priority to JP2019559413A priority patent/JP7318889B2/ja
Priority to PCT/IB2018/000216 priority patent/WO2018134685A2/en
Priority to US16/478,281 priority patent/US11518760B2/en
Priority to EP18721448.1A priority patent/EP3571204B1/en
Priority to US17/956,435 priority patent/US12545675B2/en
Priority to JP2023004747A priority patent/JP2023052427A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB1700814.5A 2017-01-17 2017-01-17 Compounds Ceased GB201700814D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB1700814.5A GB201700814D0 (en) 2017-01-17 2017-01-17 Compounds
JP2019559413A JP7318889B2 (ja) 2017-01-17 2018-01-17 化合物
PCT/IB2018/000216 WO2018134685A2 (en) 2017-01-17 2018-01-17 Compounds
US16/478,281 US11518760B2 (en) 2017-01-17 2018-01-17 Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds
EP18721448.1A EP3571204B1 (en) 2017-01-17 2018-01-17 Compounds
US17/956,435 US12545675B2 (en) 2017-01-17 2022-09-29 Anti-wolbachia pyrido[2,3-d]pyrimidine compounds
JP2023004747A JP2023052427A (ja) 2017-01-17 2023-01-16 化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1700814.5A GB201700814D0 (en) 2017-01-17 2017-01-17 Compounds

Publications (1)

Publication Number Publication Date
GB201700814D0 true GB201700814D0 (en) 2017-03-01

Family

ID=58463323

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1700814.5A Ceased GB201700814D0 (en) 2017-01-17 2017-01-17 Compounds

Country Status (5)

Country Link
US (2) US11518760B2 (cg-RX-API-DMAC10.html)
EP (1) EP3571204B1 (cg-RX-API-DMAC10.html)
JP (2) JP7318889B2 (cg-RX-API-DMAC10.html)
GB (1) GB201700814D0 (cg-RX-API-DMAC10.html)
WO (1) WO2018134685A2 (cg-RX-API-DMAC10.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
SG11202012973RA (en) 2018-06-27 2021-01-28 Bristol Myers Squibb Co Naphthyridinone compounds useful as t cell activators
CN109627207A (zh) * 2018-12-17 2019-04-16 天津药明康德新药开发有限公司 一种3-(二氟甲氧基)哌啶盐酸盐的制备方法
CN109651171A (zh) * 2019-01-13 2019-04-19 苏州鹏旭医药科技有限公司 依拉戈利及其钠盐的中间体及其盐的制备方法和应用
AU2020222881C1 (en) 2019-02-13 2026-01-22 Ptc Therapeutics, Inc. Thioeno(3,2-b) pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
WO2020180768A1 (en) * 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
KR102923602B1 (ko) * 2019-05-31 2026-02-06 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 피리도피리미딘 유도체
MA56022A (fr) 2019-05-31 2022-04-06 Chiesi Farm Spa Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
KR20220113700A (ko) * 2019-12-12 2022-08-16 피티씨 테라퓨틱스, 인크. 가족성 자율신경실조증 치료를 위한 화합물
CA3162979A1 (en) 2019-12-23 2021-07-01 Upender Velaparthi Substituted piperazine derivatives useful as t cell activators
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
IL294148A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinazolinyl compounds are useful as t-cell activators
TW202208355A (zh) * 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
WO2022058896A1 (en) * 2020-09-15 2022-03-24 Cadila Healthcare Limited Inhibitors of low molecular weight protein tyrosine phosphatase for management of metabolic disorder
US20230357239A1 (en) 2020-09-18 2023-11-09 Bayer Aktiengesellschaft Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
GB202100635D0 (en) 2021-01-18 2021-03-03 Liverpool School Tropical Medicine Compounds and methods for treating or preventing dirofilaria infection in a mammal
WO2022171018A1 (zh) * 2021-02-09 2022-08-18 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
WO2022187411A1 (en) 2021-03-02 2022-09-09 Kumquat Biosciences Inc. Heterocycles and uses thereof
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
EP4511128A1 (en) 2022-04-20 2025-02-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
CN115160294B (zh) * 2022-06-27 2023-09-29 中山大学 一种G9a/GLP共价抑制剂及其制备方法及应用
WO2024056782A1 (en) 2022-09-16 2024-03-21 Bayer Aktiengesellschaft Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer
CN120112538A (zh) 2022-10-13 2025-06-06 拜耳公司 Sos1抑制剂
TW202430519A (zh) * 2022-11-28 2024-08-01 大陸商上海美悅生物科技發展有限公司 螺雜環取代的嘧啶類化合物及其製備方法和用途
JP2026524539A (ja) * 2023-07-11 2026-07-22 テイ・セラピューティクス・リミテッド Ｐｔｃリードスルー剤としてのナフチリジン又はピリドピリミジン核を含む化合物
AR134833A1 (es) * 2024-01-05 2026-04-15 Dewpoint Therapeutics Inc Compuestos de tienopiridina y sus usos
CN119161336B (zh) * 2024-07-24 2025-09-05 四川大学 一种作为Blimp1抑制剂的小分子化合物及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
US6262059B1 (en) * 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6103903A (en) 1998-02-26 2000-08-15 Neurogen Corporation 4-(4-piperidylmethyhlamino) substituted heteroaryl fused pyridines: GABA brain receptor ligands
SV2002000205A (es) * 1999-11-01 2002-06-07 Lilly Co Eli Compuestos farmaceuticos ref. x-01095
WO2003055890A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
CA2549510A1 (en) 2003-12-16 2005-07-07 Pfizer Products Inc. Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
WO2007063934A1 (ja) * 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 脂環式複素環化合物
US8027888B2 (en) * 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
CA2691932A1 (en) * 2007-06-27 2008-12-31 Summit Corporation Plc Use of compounds for preparing anti-tuberculosis agents
WO2010042489A2 (en) * 2008-10-06 2010-04-15 Emory University Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
PH12012500097A1 (en) * 2009-07-21 2011-01-27 Shanghai Inst Organic Chem Potent small molecule inhibitors of autophagy, and methods of use thereof
FR2959510B1 (fr) * 2010-04-28 2013-04-26 Centre Nat Rech Scient Derives de pyrido[3,2-d]pyrimidine, leurs procedes de preparation et leurs utilisations therapeutiques
US20130345249A1 (en) * 2011-01-15 2013-12-26 The Regents Of The University Of California Formulations for the prevention and treatment of Wolbachia-related disease
EP2532661A1 (en) 2011-06-10 2012-12-12 Syngenta Participations AG Novel insecticides
CN103087077B (zh) 2011-11-03 2016-05-18 上海希迈医药科技有限公司 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用
CN103204816B (zh) 2012-01-16 2016-04-27 中国人民解放军军事医学科学院毒物药物研究所 哌嗪基嘧啶类衍生物及其制备方法和用途
HK1246679A1 (zh) 2015-01-09 2018-09-14 Abbvie Inc. 丝虫病的治疗
SG11201606876RA (en) * 2015-03-04 2016-10-28 Gilead Sciences Inc Toll like receptor modulator compounds
CN106083742A (zh) 2016-05-31 2016-11-09 广东工业大学 一种2,4‑二胺基喹唑啉衍生物及其制备方法和应用
US20190345175A1 (en) 2016-12-09 2019-11-14 Wacker Chemie Ag Methof for producing hydridosilanes
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
CN110128419A (zh) 2019-05-17 2019-08-16 南开大学 一类二氟吡唑杂环甲酰胺类衍生物及其制备方法和用途
GB202100635D0 (en) 2021-01-18 2021-03-03 Liverpool School Tropical Medicine Compounds and methods for treating or preventing dirofilaria infection in a mammal
KR102682408B1 (ko) 2021-05-12 2024-07-05 에이치케이이노엔 주식회사 신규한 벤조티아졸 유도체, 이의 제조방법 및 이의 간질환 예방 또는 치료 용도
TW202329955A (zh) 2022-01-12 2023-08-01 英屬開曼群島商百濟神州有限公司 作為ＤＮＡ聚合酶Ｔｈｅｔａ抑製劑之噻唑并吡啶基醯胺衍生物
EP4464709A4 (en) 2022-01-13 2025-12-24 Nanjing Zaiming Pharmaceutical Co Ltd SIX-LINKED CYCLOTHIAZOLE COMPOUND AND ITS USE

Also Published As

Publication number Publication date
JP2020505454A (ja) 2020-02-20
WO2018134685A2 (en) 2018-07-26
US11518760B2 (en) 2022-12-06
JP7318889B2 (ja) 2023-08-01
JP2023052427A (ja) 2023-04-11
EP3571204A2 (en) 2019-11-27
US12545675B2 (en) 2026-02-10
US20190345157A1 (en) 2019-11-14
US20230348460A1 (en) 2023-11-02
EP3571204B1 (en) 2026-07-29
WO2018134685A3 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
GB201708456D0 (en) Senolytic compounds
GB201704327D0 (en) Compounds
GB201715342D0 (en) Compounds
GB201704325D0 (en) Compounds
SI4039675T1 (sl) Fenil-2-hidroksi-acetilamino-2-metil-fenilne spojine
GB201716871D0 (en) Compounds
GB201713962D0 (en) Compounds
GB201717051D0 (en) Compounds
GB201707938D0 (en) Compounds
GB201707856D0 (en) Compounds
GB201702221D0 (en) Compounds
GB201716369D0 (en) Compounds
GB201715786D0 (en) Compounds
GB201720064D0 (en) Compounds
GB201716392D0 (en) Compounds
GB201707852D0 (en) Compounds
GB201703282D0 (en) Compounds
GB201721758D0 (en) Compounds
GB201721326D0 (en) Compounds
GB201721330D0 (en) Compounds
GB201721331D0 (en) Compounds
GB201720495D0 (en) ß-lactone compounds
GB201719261D0 (en) Compounds
GB201717718D0 (en) Compounds
GB201717050D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)